Study Details

General Information

Pfizer DMD2

A 6-Week, Phase 2A Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety, Tolerability and Pharmacodynamics of Oral PF-05175157 Administered With Canagliflozin in Adult Subjects with Type 2 Diabetes Mellitus.

ProtocolB1731006
Identifier
UID81dfaee3-61c7-448a-bc87-407d3aa4385b
StatusNot Selected
Phase2A
CategoryDiabetes Type 2 / Adult
Launch Year0
NCT Number-
Created2014-02-03 19:13
Last Updated2014-02-03 19:13

Description

No description provided.

Comment

No comment.

Target Dates

NameDateRequired
Enrollment ClosedNo
Enrollment OpenNo
First Patient First VisitNo
Site Initiation Mtg.No
PI Meeting StartNo
PI Meeting EndNo
PI Meeting ArrivalNo
PI Meeting DepartureNo
Closeout DateNo
Final PatientVisitNo
PreStudy Selection VisitNo
Target Date 12No
Target Date 13No
Target Date 14No

Leadership

RoleStaffLoginRequired
PrincipalMartinez, GilbertGJMartinezNo
Recruiter-No
Coordinator-No
RegulatoryAguirre, SandraSAguirreNo

Custom Fields

No custom fields.

Sponsor & Organization

SponsorPfizer
DivisionPfizer
TeamPfizer
Managing SiteCatalina Research Institute, LLC
Organization

Contacts

IRB Ref
CRO
CRO Ref
Correspondence0

Opportunity

Probability0
Comment
Status ColorLightgray
Currency-
Mayra Sibley

2 Hours

Hi there, I'm Jesse and you?
You

3 minutes

My name is Anne Clarc.
Mayra Sibley

40 seconds

Nice to meet you Anne.
How can i help you?